By contrast, mutations in TP53 and ERBB2/ERBB3 were more frequent in papillary carcinomas (60% for TP53, 80% for ERBB2/ERBB3) than in ICPNs (14.2% for TP53, 14.2% for ERBB2/ERBB3). This evidence concerns the gene ERBB3 and papillary carcinoma.